Jingtai Holdings (02228) collaborates with LABORATOIRES PIERRE FABRE for AI-driven drug discovery

Zhitongcaijing · 6d ago

Zhitong Financial App News, Jingtai Holdings (02228) announced that QuantumPharm Limited and Jingtai Intelligent Pharmaceutical Technology (Shanghai) Co., Ltd. (both wholly-owned subsidiaries of the Company) and Pierre Fabre Médicament SAS (Laboratoires Pierre Fabre Group member company, “Laboratoires Pierre Fabre”) have signed a research cooperation agreement (cooperation). The Group and Laboratoires Pierre Fabre will collaborate on the discovery of novel clinical drug candidates in various research projects in the field of oncology, possibly covering the fields of dermatology and rare diseases.

Under the cooperation, the Group will use its integrated AI capabilities and robotics platform to design and deliver novel small molecule therapeutics for undisclosed targets from scratch. Laboratoires Pierre Fabre will contribute its expertise in disease biology, drug discovery, translational research and clinical development to select and advance the most promising compounds, and will be responsible for subsequent clinical and commercial development.

The cooperation reflects the mutual interest of both sides in exploring challenging and historically difficult drug targets. There are many unmet medical needs in this field, and there are significant opportunities for innovative drug discovery. Through this collaboration, the two sides aim to accelerate the identification of high-quality clinical drug candidates in various research projects in oncology and other potential treatment fields.

The partnership includes upfront payments, multi-milestone payments, and subsequent economic sharing.

The board of directors believes that cooperation to advance the Group's work to apply artificial intelligence and robotics to drug discovery from scratch will consolidate the Group's position in the field of artificial intelligence and robot-driven drug discovery, and conform to the overall interests of the Company and its shareholders.